Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALLR Allarity Therapeutics	$0.98 -2.0%	$0.98	$0.61 ▼ $6.00	$15.08M	0.08	491,438 shs	262,920 shs
ANL Adlai Nortye	$1.76 +8.0%	$1.54	$1.10 ▼ $3.89	$60.15M	-0.95	5,442 shs	6,636 shs
BMEA Biomea Fusion	$1.69 -1.7%	$1.91	$1.29 ▼ $13.07	$64.62M	-0.14	795,759 shs	219,253 shs
DRRX DURECT	$1.90	$0.94	$0.48 ▼ $2.64	$58.98M	0.83	2.94 million shs	304,474 shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALLR Allarity Therapeutics	+4.17%	-1.00%	-4.77%	-1.00%	-77.66%
ANL Adlai Nortye	+0.92%	+5.03%	+9.27%	-12.70%	-47.78%
BMEA Biomea Fusion	+4.24%	+8.18%	-11.34%	+20.28%	-69.88%
DRRX DURECT	-0.52%	+2.15%	+239.23%	+207.64%	+34.75%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALLR Allarity Therapeutics	3.1158 of 5 stars	3.5	4.0	0.0	3.3	0.0	1.3
ANL Adlai Nortye	2.0793 of 5 stars	3.0	5.0	0.0	2.7	0.0	0.0
BMEA Biomea Fusion	3.6442 of 5 stars	4.6	3.0	0.0	1.9	2.5	0.6
DRRX DURECT	1.1332 of 5 stars	0.0	3.0	4.4	3.1	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALLR Allarity Therapeutics	3.00	Buy	$9.00	818.55% Upside
ANL Adlai Nortye	2.00	Hold	$9.00	411.36% Upside
BMEA Biomea Fusion	3.17	Buy	$16.80	894.08% Upside
DRRX DURECT	2.00	Hold	N/A	N/A

Current Analyst Ratings Breakdown

Latest ALLR, DRRX, BMEA, and ANL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2025	BMEA Biomea Fusion	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$9.00 ➝ $7.00
8/6/2025	BMEA Biomea Fusion	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$30.00 ➝ $10.00
8/6/2025	BMEA Biomea Fusion	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
8/5/2025	BMEA Biomea Fusion	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
7/29/2025	DRRX DURECT	Northland Capmk Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/28/2025	ALLR Allarity Therapeutics	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$9.00
7/21/2025	BMEA Biomea Fusion	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
7/16/2025	BMEA Biomea Fusion	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$22.00 ➝ $9.00
6/24/2025	BMEA Biomea Fusion	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
6/13/2025	BMEA Biomea Fusion	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
6/3/2025	BMEA Biomea Fusion	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$7.00

(Data available from 8/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALLR Allarity Therapeutics	N/A	N/A	N/A	N/A	$1.62 per share	N/A
ANL Adlai Nortye	$5M	12.99	N/A	N/A	$0.69 per share	2.55
BMEA Biomea Fusion	N/A	N/A	N/A	N/A	$0.73 per share	N/A
DRRX DURECT	$2.03M	29.05	N/A	N/A	$0.29 per share	6.55

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALLR Allarity Therapeutics	-$24.51M	N/A	0.00	N/A	N/A	N/A	-147.94%	-90.33%	8/18/2025 (Estimated)
ANL Adlai Nortye	-$51.87M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
BMEA Biomea Fusion	-$138.43M	-$3.03	0.00	N/A	N/A	N/A	-243.95%	-140.74%	N/A
DRRX DURECT	-$8.32M	-$0.10	N/A	N/A	N/A	-96.19%	-237.49%	-65.67%	N/A

Latest ALLR, DRRX, BMEA, and ANL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/18/2025	N/A	ALLR Allarity Therapeutics	-$0.21	N/A	N/A	N/A	N/A	N/A
8/12/2025	Q2 2025	DRRX DURECT	-$0.13	-$0.07	+$0.06	-$0.07	$0.32 million	$0.45 million
8/5/2025	Q2 2025	BMEA Biomea Fusion	-$0.59	-$0.51	+$0.08	-$0.51	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALLR Allarity Therapeutics	N/A	N/A	N/A	N/A	N/A
ANL Adlai Nortye	N/A	N/A	N/A	N/A	N/A
BMEA Biomea Fusion	N/A	N/A	N/A	N/A	N/A
DRRX DURECT	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALLR Allarity Therapeutics	N/A	2.66	2.66
ANL Adlai Nortye	0.02	1.41	1.41
BMEA Biomea Fusion	N/A	3.68	3.68
DRRX DURECT	N/A	1.23	1.22

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALLR Allarity Therapeutics	11.53%
ANL Adlai Nortye	35.21%
BMEA Biomea Fusion	96.72%
DRRX DURECT	28.03%

Insider Ownership

Company	Insider Ownership
ALLR Allarity Therapeutics	0.08%
ANL Adlai Nortye	N/A
BMEA Biomea Fusion	18.42%
DRRX DURECT	3.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALLR Allarity Therapeutics	10	15.08 million	15.07 million	Not Optionable
ANL Adlai Nortye	127	36.90 million	N/A	Not Optionable
BMEA Biomea Fusion	50	37.57 million	30.65 million	Optionable
DRRX DURECT	80	31.04 million	30.05 million	Optionable

ALLR, DRRX, BMEA, and ANL Headlines

Recent News About These Companies

DURECT (NASDAQ:DRRX) Releases Earnings Results, Beats Expectations By $0.06 EPS

2 hours ago | marketbeat.com

Durect Posts Narrower Loss in Fiscal Q2

August 13 at 3:19 AM | aol.comA

Durect, Bausch Health merger expected to close in Q3

August 12 at 10:18 PM | msn.com

Durect options imply 6.9% move in share price post-earnings

August 12 at 10:18 PM | msn.com

Durect (DRRX) Reports Q2 Loss, Tops Revenue Estimates

August 12 at 7:06 PM | zacks.com

DURECT Corporation Reports Second Quarter 2025 Financial Results and Provides Update on ...

August 12 at 5:24 PM | gurufocus.com

Durect: Q2 Earnings Snapshot

August 12 at 5:12 PM | houstonchronicle.comH

DURECT Corporation Reports Second Quarter 2025 Financial Results and Provides Update on Proposed Acquisition by Bausch Health

August 12 at 4:30 PM | prnewswire.com

Dalton Investments Inc. Has $411,000 Holdings in DURECT Corporation (NASDAQ:DRRX)

August 12 at 7:30 AM | marketbeat.com

DURECT (NASDAQ:DRRX) Stock Passes Above 200-Day Moving Average - Time to Sell?

August 10, 2025 | marketbeat.com

Bausch Health to Acquire DURECT Corporation in $63M Deal to Advance Liver Disease Treatment

August 9, 2025 | insidermonkey.com

Bausch Health to Acquire DURECT Corporation in $63M Deal to Advance Liver Disease Treatment

August 8, 2025 | msn.com

Durect Extends Tender Offer Deadline in Merger

August 8, 2025 | tipranks.com

DURECT (DRRX) Projected to Post Quarterly Earnings on Tuesday

August 6, 2025 | marketbeat.com

DURECT (NASDAQ:DRRX) Stock Price Passes Above Two Hundred Day Moving Average - Should You Sell?

August 2, 2025 | marketbeat.com

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of DURECT Corporation (NASDAQ: DRRX)

July 31, 2025 | globenewswire.com

Bausch Health expands liver disease portfolio with DURECT Corp buy

July 31, 2025 | thepharmaletter.comT

Bausch Health Adds Late-Stage Ready Alcohol Liver Disease Drug Candidate In $63 Million DURECT Buyout

July 29, 2025 | benzinga.com

DRRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of DURECT Corporation Is Fair to Shareholders

July 29, 2025 | tmcnet.com

Shareholder Alert: The Ademi Firm Investigates Whether DURECT Corporation Is Obtaining a Fair Price for Its Public Shareholders

July 29, 2025 | tmcnet.com

Bausch Health stock rises, Durect flies after acquisition deal

July 29, 2025 | za.investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALLR, DRRX, BMEA, and ANL Company Descriptions

Allarity Therapeutics NASDAQ:ALLR

$0.98 -0.02 (-2.01%)

Closing price 04:00 PM Eastern

Extended Trading

$0.98 0.00 (-0.39%)

As of 07:57 PM Eastern

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.

Adlai Nortye NASDAQ:ANL

$1.76 +0.13 (+7.98%)

Closing price 03:55 PM Eastern

Extended Trading

$1.77 +0.01 (+0.57%)

As of 04:10 PM Eastern

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trial to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.

Biomea Fusion NASDAQ:BMEA

$1.69 -0.03 (-1.74%)

Closing price 04:00 PM Eastern

Extended Trading

$1.68 0.00 (-0.30%)

As of 07:40 PM Eastern

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.

DURECT NASDAQ:DRRX

$1.90 0.00 (0.00%)

As of 04:00 PM Eastern

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. It also offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in other countries. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time